Better Bet Than Medtronic Stock: Pay Less To Get More From LIVN, CNMD
LIVN, CNMD are MDT’s peers in Health Care Equipment industry that have:
1) Lower valuation (P/EBIT) compared to MDT
2) But higher revenue and operating income growth
This disconnect between valuation and performance could mean that you are better off buying LIVN, CNMD stocks vs. MDT
Key Metrics Compared
- RMD, MDT Top Revvity Stock on Price & Potential
- Large Cap Stocks Trading At 52-Week High
- Ten-Year Tally: MDT Hands Back $52 Bil to Shareholders
- Large Cap Stocks Trading At 52-Week High
- S&P 500 Movers | Winners: ADI, MCK, MDT | Losers: INTC, TGT, DELL
- How To Trade Medtronic Stock Ahead of Its Earnings?
| Metric | MDT | LIVN | CNMD |
|---|---|---|---|
| P/OpInc* | 19.3x | 16.0x | 8.7x |
| LTM OpInc Growth | -3.1% | 302.9% | 26.8% |
| 3Y Avg OpInc Growth | 0.6% | 161.4% | 39.2% |
| LTM Revenue Growth | 2.7% | 7.6% | 4.3% |
| 3Y Avg Revenue Growth | 1.5% | 7.6% | 8.9% |
OpInc = Operating Income, P/EBIT = Price To Operating Income Ratio
Medtronic (MDT) develops and sells device-based medical therapies across cardiovascular, neuroscience, surgical, and diabetes segments, serving various specialists including surgeons, neurologists, and pain management experts.
This is just one approach to evaluate investments. Trefis High Quality Portfolio evaluates much more, and is designed to reduce stock-specific risk while giving upside exposure
Is The Mismatch In Stock Price Temporary
One way to check if Medtronic stock is expensive now versus the other tickers would be to see how these metrics compared across companies exactly a year ago. Specifically, if there has been a marked reversal in the trend for Medtronic in the last 12 months, then there is a chance that the current mismatch is likely to reverse. On the other hand, a persistent underperformance in revenue and operating income growth for Medtronic would reinforce the conclusion that the stock is expensive compared to its peers, but may not revert soon
Key Metrics Compared 1 Yr Prior
| Metric | MDT | LIVN | CNMD |
|---|---|---|---|
| P/OpInc* | 17.5x | 18.8x | 10.1x |
| LTM OpInc Growth | -5.3% | 500.9% | 66.1% |
| 3Y Avg OpInc Growth | 0.7% | 2418.8% | 34.0% |
| LTM Revenue Growth | 3.2% | 8.7% | 5.0% |
| 3Y Avg Revenue Growth | 1.3% | 6.7% | 9.2% |
OpInc = Operating Income
Additional Metrics To Consider
| Metric | MDT | LIVN | CNMD |
|---|---|---|---|
| P/S | 3.5x | 2.0x | 1.2x |
| Market Cap (Current) | $ 114.6 Bil | $ 2.6 Bil | $ 1.6 Bil |
| LTM Revenue | $ 33.20 Bil | $ 1.28 Bil | $ 1.32 Bil |
| LTM Opinc | $ 5.95 Bil | $ 161.42 Mil | $ 181.27 Mil |
| LTM Op Margin | 17.9% | 12.7% | 13.8% |
OpInc = Operating Income
Alternate buying based on valuation, while attractive, needs to be evaluated carefully from multiple angles. Such multi-factor analysis is exactly how we construct Trefis portfolio strategies. If you want upside with a smoother ride than an individual stock, consider the High Quality portfolio, which has outperformed the S&P, and clocked >91% returns since inception.